Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy of cetuximab or cetuximab-irinotecan
in patients with neo wild-type colorectal cancer who have been previously treated for
metastatic disease.
Patients will be included in cohort #1 or cohort #2. The inclusion in cohort #2 will start
when the results of the cohort #1 are available.
Patient will receive either cetuximab alone (cohort #1) or cetuximab with irinotecan (cohort
#2).